Cost ManagementThe company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.
Financial Performance1Q25 group results beat expectations, with revenues declining a more modest 6% compared to a 14% expected decline.
Market PositionSublocade retains a dominant market share with approximately 80% share within the cohort for buprenorphine-based LAI and 60% share of LAI-naive patients.